Oncology Hematology Care Inc. (Kenwood)

Cincinnati, OH

Sorting 8 by

Accepting patients

EXCALIBER - Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
  • CELMoD
  • Randomization
  • Post-Autologous Stem Cell Transplant
  • Phase 3

Accepting patients

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results

Accepting patients

SubQSA

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

Etentamig (ABBV-383)

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
  • Monoclonal Antibody
  • CD38
  • Randomization
  • Maintenance
  • Phase 3

Not currently accepting

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

Early Detection Blood Tests

Blinded Reference Set for Multicancer Early Detection Blood Tests
  • Observational Trial